A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

NCT02193113 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Edema

Interventions

DRUG: KVD001 Injection

Sponsor

KalVista Pharmaceuticals, Ltd.

Collaborators

[object Object]